Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07551167
PHASE1

A Phase I Study of HRS-5765 in Healthy Participants

Sponsor: Chengdu Suncadia Medicine Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.

Official title: A Randomized, Double-Blind, Dose-Escalation, Placebo-Parallel Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HRS-5765 in Healthy Subjects, as Well as the Effect of Food on the Pharmacokinetics of HRS-5765 and the Effect of HRS-5765 on CYP3A4 Metabolic Enzymes

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

74

Start Date

2026-04

Completion Date

2027-01

Last Updated

2026-04-24

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

HRS-5765 Tablet

HRS-5765 tablet, specified dose on specified day.

DRUG

HRS-5765 Tablet Placebo

HRS-5765 tablet placebo, specified dose on specified day.

Locations (1)

Beijing Anzhen Hospital, Capital Medical University

Beijing, Beijing Municipality, China